Concentration of hepatocyte growth factor and thrombospondin predict treatment response in patients with multiple myeloma;Koncentrace hepatocytárního růstového faktoru a trombospondinu predikuje léčebnou odpověd' u pacientů s mnohočetným myelomem

Transfuze a Hematologie Dnes

Volumn 16, Issue 1, 2010, Pages 30-34

  Šváchová, Hana ^a   Pour, L ^a   Almasa M ^a   Nemec P ^a   Kralova D ^a   Kovarova L ^b   Penka, M ^b   Vorlicek J ^a   Hajek R ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Angiogenesis; Bortezomib; HGF; Multiple myeloma; Thrombospondin

Indexed keywords

BORTEZOMIB; SCATTER FACTOR; THROMBOSPONDIN;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CANCER REGRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PROGNOSIS; TREATMENT RESPONSE;

EID: 77952528168     PISSN: 12135763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and, progression in multiple myeloma. Br J Haematol 1994; 87: 503-508. (Pubitemid 24230014)
2. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116. (Pubitemid 30637735)
3. Rajkumar SV, Yoon SY, Li CY, et al. Angiogenesis in myeloma: expression, of basic, fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells. Blood 1999; 94: 303b.
4. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in, progressive multiple, myeloma is not mediated by inhibition of angiogenic, cytokine secretion. Br J Haematol 2001; 115: 605-608. (Pubitemid 34015650)
5. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in muliple myeloma. Eur J Haematol 2001; 66: 83-88. (Pubitemid 32154100)
6. Ščudla V, Bačovský J, Papajík T, et al. Comparison of serum levels of, selected biological parameters in monoclonal gammopathy of, undetermined significance and multiple myeloma. Vnitr Lek 2006; 52: 232-240.
7. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003; 72: 229-233. (Pubitemid 36383972)
8. Pour L, Svachova H, Adam Z, et al. Pretreatment hepatocyte growth factor .and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma, Neoplasma, in print.
9. Standal T, Abildgaard N, Fagerli U, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007; 109: 3024-3030. (Pubitemid 46482103)
10. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617. (Pubitemid 36741588)
11. San Miguel JF, Schlag R, Khuageva NK, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple .myeloma. N Engl J Med 2008; 359: 906-917.
12. Papageorgiou A, Kamat A, Benedict WF, et al. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006; 5: 3032-3041. (Pubitemid 46092044)
13. Roccaro AM, Hideshima T, Raje N. Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. Cancer Res 2006; 66: 184-191.
14. Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 247-256.
15. Politou M, Naresh K, Terpos E, et al. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol 2005; 114: 170-173. (Pubitemid 41540343)
16. Cibeira MT, Rozman M, Segarra M et al. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 2008; 41: 244-253.
17. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
18. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-199. (Pubitemid 43148652)
19. Urbanska-Rys J. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Mediators Inflamm 2003; 12: 229-235.
20. Dmoszynska A, Bojarska-Junak A, Domanski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2003; 44: 1347-1351.
21. Pour L, Kovarova L, Buchler T, et al. Evaluation of hepatocyte growth factor and endostatin in the bone marrow of patients with multiple myeloma and the effect of peripheral blood admixture. Scripta medica 2009; in print.
22. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176-185. (Pubitemid 46978271)
23. Němec P, Grešliková H, Smetana J, et al. The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen. Haematologica/The Hematology Journal 2008; 93(Suppl 1): 227-228.
24. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. DOXIL-MMY-3001 Study Investigators Cancer 2008; 112: 1529-.1537.
25. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164. (Pubitemid 44401612)
26. Attal M, Harousseau JL, Facon T, et al. InterGroupe Francophone du Myelome.: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med, 2003; 349: 2495-2502. Erratum in: N Engl J Med 2004; 350: 2628.
27. Maisnar V, Radocha J, Büchler T, et al. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. Eur J Haematol 2007; 79: 305-309. (Pubitemid 47390139)